The Impact of Methylprednisolone Pulses during Relapses of Multiple Sclerosis on the Kinetics of Anti-Interferon-Beta Antibodies

被引：0
|
作者：
Giantzi, Virginia [1 ]
Karapanayiotides, Theodoros [1 ]
Lagoudaki, Roza [1 ,2 ]
Poulatsidou, Kyriaki-Nefeli [1 ,2 ]
Lourbopoulos, Athanasios [1 ,2 ]
Daniilidis, Michail [1 ,2 ]
Taskos, Nikolaos [1 ]
Milonas, Loannis [1 ]
Grigoriadis, Nikolaos [1 ,2 ]
机构：
[1] Aristotle Univ Thessaloniki, AHEPA Univ Hosp, Dept Neurol 2, GR-54006 Thessaloniki, Greece
[2] Aristotle Univ Thessaloniki, AHEPA Univ Hosp, Lab Expt Neurol & Neuroimmunol, GR-54006 Thessaloniki, Greece
来源：
EUROPEAN NEUROLOGY | 2016年 / 75卷 / 1-2期
关键词：
Neutralizing antibodies; Binding antibodies; Anti-interferon-beta antibodies; Multiple sclerosis; NEUTRALIZING ANTIBODIES; IFN-BETA; DIAGNOSTIC-CRITERIA; BINDING-ANTIBODIES; MS; CORTICOSTEROIDS; IFN-BETA-1B; THERAPY; TRIAL;
D O I：
10.1159/000444319
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
Background/Aims: We assessed the, hitherto unknown, impact of intravenous methylprednisolone (ivMP) pulses during relapses of multiple sclerosis (MS) on the kinetics of anti-interferon-beta neutralizing antibodies (Nabs) and binding antibodies (Babs). Methods: Babs (ELISA) and Nabs (antiviral cytopathic effect assay) titers were evaluated before, immediately after and at 1 month following ivMP in 60 MS patients. Results: ivMP reduces Nabs and Babs titers for at least 1 month. Baseline titers determine Nabs and Babs seronegativity at the end of ivMP. Clinical response to ivMP tends to be better in Nabs(+) patients. Conclusion: Sampling for Nabs/Babs should be avoided during or shortly after ivMP to avoid transient positive or negative results that may obscure the decision to switch treatment. (C) 2016 S. Karger AG, Basel
引用
收藏
页码：82 / 88
页数：7
相关论文
共 50 条
  • [1] Clinical utility of anti-interferon-beta antibodies in patients with multiple sclerosis
    Pietrzak, Anna
    Michalak, Slawomir
    Kozubski, Wojciech
    AKTUALNOSCI NEUROLOGICZNE, 2016, 16 (02): : 92 - 98
  • [2] Correlation between anti-interferon-beta binding and neutralising antibodies in multiple sclerosis patients on interferon-beta therapy
    Jensen, P. E. H.
    Sellebjerg, F.
    Sondergaard, H. B.
    Sorensen, P. S.
    MULTIPLE SCLEROSIS JOURNAL, 2011, 17 : S120 - S120
  • [3] Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort study
    Jensen, Poul Erik H.
    Warnke, Clemens
    Ingenhoven, Kathleen
    Piccoli, Luca
    Gasis, Marcia
    Hermanrud, Christina
    Fernandez-Rodriguez, Blanca M.
    Ryner, Malin
    Kramer, Daniel
    Link, Jenny
    Ramanujam, Ryan
    Auer, Michael
    Buck, Dorothea
    Grummel, Verena
    Bertotti, Elisa
    Fissolo, Nicolas
    Oliver-Martos, Begona
    Nytrova, Petra
    Khalil, Michael
    Guger, Michael
    Rathmaier, Sandra
    Sievers-Stober, Claudia
    Lindberg, Raija L. P.
    Hassler, Signe
    Bachelet, Delphine
    Aktas, Orhan
    Donnellan, Naoimh
    Lawton, Andy
    Hemmer, Bernhard
    Havrdova, Eva Kubala
    Kieseier, Bernd
    Hartung, Hans-Peter
    Comabella, Manuel
    Montalban, Xavier
    Derfuss, Tobias
    Sellebjerg, Finn
    Donnes, Pierre
    Pallardy, Marc
    Spindeldreher, Sebastian
    Broet, Philippe
    Deisenhammer, Florian
    Fogdell-Hahn, Anna
    Sorensen, Per Soelberg
    JOURNAL OF NEUROIMMUNOLOGY, 2019, 326 : 19 - 27
  • [4] Anti-interferon-beta neutralising activity is not entirely mediated by antibodies
    Gilli, F
    Sala, A
    Hoffmann, F
    Marnetto, F
    Caldano, M
    Kappos, L
    Bertolotto, A
    Lindberg, RLP
    MULTIPLE SCLEROSIS, 2005, 11 : S2 - S3
  • [5] A comparative study of development of anti-interferon-beta antibodies in a randomized study of interferon-beta 1b and interferon beta 1a in patients with multiple sclerosis
    Sorensen, PS
    Ross, C
    Koch-Henriksen, N
    Svenson, M
    Skovgaard, GL
    Bendtzen, K
    NEUROLOGY, 1999, 52 (06) : A491 - A491
  • [6] Anti-interferon-beta antibodies in Polish multiple sclerosis patients: prevalence and clinical significance in a long-term prospective study
    Pietrzak, Anna
    Kalinowska-Lyszczarz, Alicja
    Osztynowicz, Krystyna
    Khamidulla, Alima
    Kozubski, Wojciech
    Michalak, Slawomir
    NEUROLOGIA I NEUROCHIRURGIA POLSKA, 2019, 53 (05) : 348 - 357
  • [7] Interferon beta in multiple sclerosis - Relapses deserve treatment
    Cardy, P
    BRITISH MEDICAL JOURNAL, 1997, 314 (7080): : 602 - 602
  • [8] Immune tolerance strategies to reverse the development of neutralising anti-interferon-beta antibodies
    Giovannoni, G.
    EUROPEAN JOURNAL OF NEUROLOGY, 2006, 13 : 302 - 302
  • [9] Neutralising antibodies to interferon beta during the treatment of multiple sclerosis
    Giovannoni, G
    Munschauer, FE
    Deisenhammer, F
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2002, 73 (05): : 465 - 469
  • [10] Dynamics of neutralizing anti-interferon antibodies in multiple sclerosis patients during interferon-beta therapy
    Sorensen, PS
    Koch-Henriksen, N
    NEUROLOGY, 2004, 62 (07) : A383 - A383
12345